NameTag is an open-source tool for named entity recognition (NER). NameTag identifies proper names in text and classifies them into predefined categories, such as names of persons, locations, organizations, etc. NameTag is distributed as a standalone tool or a library, along with trained linguistic models. In the Czech language, NameTag achieves state-of-the-art performance (Straková et al. 2013). NameTag is a free software under LGPL license and the linguistic models are free for non-commercial use and distributed under CC BY-NC-SA license, although for some models the original data used to create the model may impose additional licensing conditions.
NER models for NameTag 2, named entity recognition tool, for English, German, Dutch, Spanish and Czech. Model documentation including performance can be found here: https://ufal.mff.cuni.cz/nametag/2/models . These models are for NameTag 2, named entity recognition tool, which can be found here: https://ufal.mff.cuni.cz/nametag/2 .
NER models for NameTag 2, named entity recognition tool, for English, German, Dutch, Spanish and Czech. Model documentation including performance can be found here: https://ufal.mff.cuni.cz/nametag/2/models . These models are for NameTag 2, named entity recognition tool, which can be found here: https://ufal.mff.cuni.cz/nametag/2 .
This is a trained model for the supervised machine learning tool NameTag 3 (https://ufal.mff.cuni.cz/nametag/3/), trained jointly on several NE corpora: English CoNLL-2003, German CoNLL-2003, Dutch CoNLL-2002, Spanish CoNLL-2002, Ukrainian Lang-uk, and Czech CNEC 2.0, all harmonized to flat NEs with 4 labels PER, ORG, LOC, and MISC. NameTag 3 is an open-source tool for both flat and nested named entity recognition (NER). NameTag 3 identifies proper names in text and classifies them into a set of predefined categories, such as names of persons, locations, organizations, etc. The model documentation can be found at https://ufal.mff.cuni.cz/nametag/3/models#multilingual-conll.
Nanobiophotonics is one of the most recent interdisciplinary scientific disciplines that originated at the frontiers of nanotechnology, photonics and biomedical sciences. The aim of nanobiophotonics is to transfer the medical diagnostics and therapy to the level of individual proteins and biologically active molecules, acting as cornerstones of the living cell. One of the key roles in its advancement can be attributed to the development of ultrafast pused lasers. These allowed to cross-combine spectroscopic, imaging and time-resolved methods and provide complex, multi-modal information about biological structures and phenomena on the nanometer scale. In our contribution we give an overview of the most important moments mapping the path from the discovery of the first laser to the current state of nanobiophotonic technologies in the world, and perspectives of this new scientific field in Slovakia., Nanobiofotonika je jedným z najmladších interdisciplinárnych vedeckých smerov, ktorý vznikol na pomedzí nanotechnológií, fotoniky a biomedicínskych vied s cieľom preniesť medicínsku diagnostiku a terapiu na úroveň proteínov a biologicky aktívnych molekúl - základných jednotiek živej bunky. Kľúčovú úlohu v jeho rozvoji má predovšetkým vývoj pulzných laserov s ultrakrátkymi impulzmi, ktoré umožnili prepojiť spektroskopické, zobrazovacie a časovo rozlíšené metódy a poskytujú dnes komplexnú multimodálnu informáciu o biologických štruktúrach a javoch na nanometrovej škále. V našom príspevku uvádzame prehľad vybraných významných momentov mapujúcich cestu od objavenia prvého lasera cez súčasny stav nanobiofotonických technológií k perspektívam tejto novej vednej oblasti na Slovensku., Dušan Chorvát ml., Alžbeta Chorvátová., and Obsahuje bibliografii
Neurodegenerativní onemocnění, mezi něž patří např. Alzheimerova a Parkinsonova nemoc, se kvůli své neustále se zvyšující prevalenci a nedostupnosti efektivní léčby staly jedním z nejpalčivějších problémů moderní medicíny. Ačkoli existují látky s potenciálním terapeutickým účinkem, hematoencefalická bariéra vytváří účinnou překážku pro transport léků do centrálního nervového systému. Naději pro vyřešení tohoto problému přinesl nástup nanotechnologií umožňujících přípravu částic s přesně navrženými vlastnostmi pro překročení hematoencefalické bariéry. Širokému využití nanočástic pro transport léků brání nedostatečné zmapování jejich biologických vlastností a bezpečnostních rizik. Pokrok v této oblasti společně s rostoucím porozuměním patogenezi neurodegenerativních onemocnění by v budoucnu mohl vést k nalezení jejich efektivní léčby., Due to the continually rising prevalence and lack of effective therapy, neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease, are among the most serious problems of modern medicine. Even though promising compounds with potential therapeutic effect have been developed, blood-brain barrier impedes their transport to the central nervous system. Nanotechnologies produce particles with properties that enable them to cross the blood-brain barrier and thus provide hope in solving this problem. Wide utilization of nanoparticles for transportation of drugs is prevented by our limited knowledge of their biological properties and their safety profile. Further developments in this field together with increasing understanding of the pathogenesis of neurodegeneration may lead to development of effective therapy in the future. Key words: blood-brain barrier – dendrimers – liposomes – nanotubes – carbon – nanoparticles – neurodegenerative diseases The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers., and M. Filipová, R. Rusina, K. Holada
Different strategies have been developed in the last decade to obtain fat grafts as rich as possible of mesenchymal stem cells, so exploiting their regenerative potential. Recently, a new kind of fat grafting, called "nanofat", has been obtained after several steps of fat emulsification and filtration. The final liquid suspension, virtually devoid of mature adipocytes, would improve tissue repair because of the presence of adipose mesenchymal stem cells (ASCs). However, since it is probable that many ASCs may be lost in the numerous phases of this procedure, we describe here a novel version of fat grafting, which we call "nanofat 2.0", likely richer in ASCs, obtained avoiding the final phases of the nanofat protocol. The viability, the density and proliferation rate of ASCs in nanofat 2.0 sample were compared with samples of nanofat and simple lipoaspirate. Although the density of ASCs was initially higher in lipoaspirate sample, the higher proliferation rate of cells in nanofat 2.0 virtually filled the gap within 8 days. By contrast, the density of ASCs in nanofat sample was the poorest at any time. Results show that nanofat 2.0 emulsion is considerably rich in stem cells, featuring a marked proliferation capability., D. Lo Furno, S. Tamburino, G. Mannino, E. Gili, G. Lombardo, M. S. Tarico, C. Vancheri, R. Giuffrida, R. E. Perrotta., and Obsahuje bibliografii